Penumbra (PEN) Income from Non-Controlling Interests (2018 - 2021)
Penumbra's (PEN) quarterly Income from Non-Controlling Interests came in at -$819000.0 in Q3 2021, up 22.81% year-on-year from -$666891.0 in Q3 2020, and up 12.12% on a QoQ basis from -$932000.0 in Q2 2021.
Penumbra (PEN) Income from Non-Controlling Interests (2018 - 2021) Analysis & Trends
Penumbra (PEN) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$819000.0 in Q3 2021.
- On a quarterly basis, Income from Non-Controlling Interests rose 22.81% year-over-year to -$819000.0 in Q3 2021; TTM through Jun 2022 was -$819000.0, a 79.1% increase from a year earlier, with the FY2021 full-year figure at -$2.7 million, up 25.15% from the prior year.
- Income from Non-Controlling Interests for Q3 2021 stood at -$819000.0, up from -$932000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for PEN reached as high as -$195000.0 in Q4 2018 and fell as low as -$3.5 million in Q3 2018.
- Historically, Income from Non-Controlling Interests has averaged -$873923.1 across 4 years, with a median of -$819000.0 in 2021.
- Across the five-year window, Income from Non-Controlling Interests surged 86.18% in 2019 and plunged 177.58% in 2020, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$195000.0 in 2018, then sank by 98.97% to -$388000.0 in 2019, then plunged by 161.86% to -$1.0 million in 2020, then advanced by 19.39% to -$819000.0 in 2021.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$819000.0 in Q3 2021, -$932000.0 in Q2 2021, and -$910000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -5.85 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 22.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -819,000.00 |
| Jun 30, 2021 | -932,000.00 |
| Mar 31, 2021 | -910,000.00 |
| Dec 31, 2020 | -1.02 Mn |
| Sep 30, 2020 | -1.06 Mn |
| Jun 30, 2020 | -941,000.00 |
| Mar 31, 2020 | -537,000.00 |
| Dec 31, 2019 | -388,000.00 |
| Sep 30, 2019 | -483,000.00 |
| Jun 30, 2019 | -339,000.00 |
| Mar 31, 2019 | -244,000.00 |
| Dec 31, 2018 | -195,000.00 |
| Sep 30, 2018 | -3.50 Mn |